Takeda Pharmaceutical Company Ltd. (NYSE:TAK) reported fourth-quarter sales of $6.98 billion, or 1.094 trillion yen, missing Wall Street estimates of $7.05 billion.

The Japanese drugmaker reported adjusted earnings of 28 cents per ADR (89 yen per share), beating analyst estimates of 21 cents per share.

CFO Highlights Profitability, Cash Flow Focus

Chief Financial Officer Milano Furuta said the company delivered "solid profit and cash flow through disciplined cost control" in fiscal 2025 despite revenue headwinds, while continuing to invest in product launches and its pipeline.

"In FY2026, we will continue to focus on transforming operations and protecting profitability while delivering successful launches and advancing our pipeline. Strong cash flow generation and deleveraging will support long-term investment for growth acceleration and ensure competitive returns for our shareholders," ...